GASC1-Adapted Neoadjuvant Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma: A Prospective Clinical Biomarker Trial
Joint Authors
Jia, Ruinuo
Kong, Jinyu
Gao, Shegan
Mi, Youjia
Yuan, Xiang
Kong, Dejiu
Li, Wanying
Li, Ruonan
Wang, Bingbing
Zhu, Yafei
Ma, Zhikun
Li, Na
Mi, Qiangjian
Source
Issue
Vol. 2020, Issue 2020 (31 Dec. 2020), pp.1-8, 8 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2020-01-30
Country of Publication
Egypt
No. of Pages
8
Main Subjects
Abstract EN
Neoadjuvant chemotherapy (NCT) is a standard care for esophageal squamous cell carcinoma (ESCC), but the efficacy is unsatisfactory.
Cancer stem cells (CSCs) play key roles in chemotherapy resistance.
Gene amplified in squamous cell carcinoma 1 (GASC1) is a neoteric gene in stemness maintaining of ESCC.
We aimed to reveal whether GASC1 could be a predictive biomarker for NCT in ESCC.
ESCC patients (T2-4N0-2M0) were evaluated for GASC1 expression using immunohistochemical staining and classified as GASC1-low group (GLG) and GASC1-high group (GHG).
NCT was delivered in two cycles and then the surgery was completed.
Primary endpoints were tumor regression grade (TRG) and objective response rate (ORR); secondary endpoints were radical surgical resection (R0) rate and three-year overall survival (OS).
60 patients were eligible with evaluable outcomes: 24 in GHG and 36 in GLG.
Between GHG and GLG, TRG1, TRG2, TRG3, and TRG4 were 0 : 16.7%, 20.8% : 41.7%, 58.3% : 36.1%, and 20.8% : 5.6%, respectively (P=0.006); ORR and R0 rate were 33.3% : 69.4% (P=0.006) and 75% : 94.4% (P=0.046), respectively; the median OS was 20 : 32 (months) (P=0.0356).
No significant difference in the three-year OS was observed between GHG and GLG: 29.2% : 41.7% (P=0.24).
Furthermore, the GASC1 expression level was associated with poor OS independent of other factors by univariate and multivariate analyses.
Therefore, GASC1 might be a potential biomarker to predict NCT efficacy for ESCC.
American Psychological Association (APA)
Jia, Ruinuo& Mi, Youjia& Yuan, Xiang& Kong, Dejiu& Li, Wanying& Li, Ruonan…[et al.]. 2020. GASC1-Adapted Neoadjuvant Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma: A Prospective Clinical Biomarker Trial. Journal of Oncology،Vol. 2020, no. 2020, pp.1-8.
https://search.emarefa.net/detail/BIM-1188849
Modern Language Association (MLA)
Jia, Ruinuo…[et al.]. GASC1-Adapted Neoadjuvant Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma: A Prospective Clinical Biomarker Trial. Journal of Oncology No. 2020 (2020), pp.1-8.
https://search.emarefa.net/detail/BIM-1188849
American Medical Association (AMA)
Jia, Ruinuo& Mi, Youjia& Yuan, Xiang& Kong, Dejiu& Li, Wanying& Li, Ruonan…[et al.]. GASC1-Adapted Neoadjuvant Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma: A Prospective Clinical Biomarker Trial. Journal of Oncology. 2020. Vol. 2020, no. 2020, pp.1-8.
https://search.emarefa.net/detail/BIM-1188849
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1188849